|
Sign In to gain access to subscriptions and/or personal tools.
|
Endothelium and the brain in CNS lupus
P L Meroni
Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy, pierluigi.meroni{at}unimit.it
A Tincani
Rheumatology, Allergy and Clinical Immunology, Spedali Civili, Brescia, Italy
N Sepp
Department of Dermatology, University of Innsbruck, Austria
E Raschi
Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy
C Testoni
Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy
E Corsini
IRCCS Istituto Neurologico Besta, Milan, Italy
I Cavazzana
Rheumatology, Allergy and Clinical Immunology, Spedali Civili, Brescia, Italy
S Pellegrini
Allergy and Clinical Immunology Unit, Department of Internal Medicine, University of Milan, IRCCS Istituto Auxologico Italiano, Milan, Italy
A Salmaggi
IRCCS Istituto Neurologico Besta, Milan, Italy
Central nervous system (CNS) involvement in systemic lupus erythematosus (SLE) is common and results in different clinical manifestations. Several pathogenic mechanisms have been suggested to play a rolein determiningsuch a varietyof clinicalsymptoms.The thrombophilicstateassociatedto the presence of antiphospholipidantibodies has been suggested to be responsible for a noninflammatory vasculopathywhichcauses clear ischaemiceventsas well as alterationsof the cerebralmicrocirculation that are likely associated to seizures, cognitive dysfunction or psychosis. Although less frequent, a true vasculitic process affecting cerebral circulation has also been reported. In both cases, brain endothelium does represent the target of the pathogenic mechanisms. Brain endothelial cells display peculiar functional and phenotypical characteristics in comparison with endothelial cells from other anatomical districts, raising the possibility that this might be the reason for its susceptibility in lupus disease. We review and present data suggesting that a higher and firmer expression of beta 2 glycoprotein I on endothelialcell membranes can be responsiblefor a selective damage/activation by circulating anti-beta 2 glycoprotein I, and that antiendothelial cell antibodies crossreact with brain endothelium and in some cases, specifically bind brain endothelial cells only in lupus patients with central nervous involvement.
Key Words: autoantibodies CNS endothelium SLE thrombosis
Lupus, Vol. 12, No. 12,
919-928 (2003)
DOI: 10.1191/0961203303lu503oa

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Wright, F. O'Prey, P. Hamilton, C. Lockhart, A McCann, M. McHenry, R. McGivern, R Plumb, M. Finch, A. Bell, et al.
Colour Doppler ultrasound of the ocular circulation in patients with systemic lupus erythematosus identifies altered microcirculatory haemodynamics
Lupus,
October 1, 2009;
18(11):
950 - 957.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Romay-Penabad, M. G. Montiel-Manzano, T. Shilagard, E. Papalardo, G. Vargas, A. B. Deora, M. Wang, A. T. Jacovina, E. Garcia-Latorre, E. Reyes-Maldonado, et al.
Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo
Blood,
October 1, 2009;
114(14):
3074 - 3083.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Kimura, T. Sakurai, Y. Tanaka, I. Hozumi, K. Takahashi, M. Takemura, K. Saito, M. Seishima, and T. Inuzuka
Proteomic analysis of autoantibodies in neuropsychiatric systemic lupus erythematosus patient with white matter hyperintensities on brain MRI
Lupus,
January 1, 2008;
17(1):
16 - 20.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M.L. Ishimori, B.D. Pressman, D.J. Wallace, and M.H. Weisman
Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?
Lupus,
June 1, 2007;
16(6):
436 - 443.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. F. Smith Jr and M. L. Druzin
Perinatal Implications of the Antiphospholipid Syndrome
NeoReviews,
May 1, 2007;
8(5):
e206 - e213.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Wright, F. M. O'Prey, D. J. Rea, R. D. Plumb, A. J. Gamble, W. J. Leahey, A. B. Devine, R. C. McGivern, D. G. Johnston, M. B. Finch, et al.
Microcirculatory Hemodynamics and Endothelial Dysfunction in Systemic Lupus Erythematosus
Arterioscler Thromb Vasc Biol,
October 1, 2006;
26(10):
2281 - 2287.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Cesarman-Maus, N. P. Rios-Luna, A. B. Deora, B. Huang, R. Villa, M. d. C. Cravioto, D. Alarcon-Segovia, J. Sanchez-Guerrero, and K. A. Hajjar
Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome
Blood,
June 1, 2006;
107(11):
4375 - 4382.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A Tincani, D Bompane, E Danieli, and A Doria
Pregnancy, lupus and antiphospholipid syndrome (Hughes syndrome)
Lupus,
March 1, 2006;
15(3):
156 - 160.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
L Barile-Fabris, R Ariza-Andraca, L Olguin-Ortega, L J Jara, A Fraga-Mouret, J M Miranda-Limon, J Fuentes de la Mata, P Clark, F Vargas, and J Alocer-Varela
Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus
Ann Rheum Dis,
April 1, 2005;
64(4):
620 - 625.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F Neri, L Chimini, F Bonomi, E Filippini, M Motta, D Faden, A Lojacono, C B. Rebaioli, M Frassi, E Danieli, et al.
Neuropsychological development of children born to patients with systemic lupus erythematosus
Lupus,
October 1, 2004;
13(10):
805 - 811.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
N J Abbott, L L. Mendonca, and D E. Dolman
The blood-brain barrier in systemic lupus erythematosus
Lupus,
December 1, 2003;
12(12):
908 - 915.
[Abstract]
[PDF]
|
 |
|
|
|